Reaching 14 percent growth would require many, if not all, of these trends to materialize. Whether the market will track along the expected trajectory of 10 to 12 percent or capture its upside potential will depend on how effectively the industry can harness tailwinds from growth trends and meet the emerging needs of potential new patients.
Today, overall market penetration is around 5 percent for neuromodulators and 4 percent for dermal fillers and biostimulators. Likewise, 5 percent of all dermal filler and biostimulator users were men in 2018, rising to 7 percent in 2021. Men made up 10 percent of the neuromodulator market in 2018, jumping to 15 percent in 2021. Please email us at: men still account for a minority of customers in most markets, the proportion of men utilizing aesthetics services is growing, especially in North America and Europe and in affluent social groups. If you would like information about this content we will be happy to work with you. We strive to provide individuals with disabilities equal access to our website. Patients from 20 to 30 with middle to high incomes represent a sizable portion of the market as well, with penetration of more than 10 percent among the highest earners. But 30- to 50-year-olds with incomes from $50,000 to $100,000 are also a substantial segment. Averaged across the globe, people with annual incomes exceeding $100,000 are the most active users. Our survey analyzed the utilization of neuromodulators, dermal fillers and biostimulators by age group, income level, and gender (Exhibit 2). 7Įven in the longer-established geographical markets, such as North America, the pool of potential patients is steadily expanding. But there are variations between regions for example, the core demographic is much younger in China. In most large markets, the core consumer base for aesthetics injectables continues to be affluent women over 40 seeking facial treatments.
We believe that fundamental trends and elevated concerns about aging and health were responsible for the bounce-back. Medical Insights: The global aesthetics market study XIX, November 2021 analysis includes neuromodulators and dermal fillers but not fat reduction injectables.
5Ĭapital IQ, stock performance of a sample of aesthetics players compared with S&P 500 from 2007 to 2010.Īfter contracting by a moderate 7 percent in 2020, the aesthetics market rebounded swiftly in 2021, aided by a post Covid increased consciousness and focus on aesthetics procedures. The COVID-19 pandemic underscored the resilience of the aesthetics injectables market, which had already been evident in a previous crisis: during the 2008 recession it lost only 2.4 percent of its sales and less than 20 percent of its market capitalization while the S&P 500 Index contracted by 50 percent.
0 kommentar(er)
